Foster-Cheek Kaye I
SEC insider (Form 3/4/5 filer). CIK 0001312622. Director at AGIOS PHARMACEUTICALS, INC. (AGIO) and 1 other issuer. 16 reported Form 4/5 transactions since Sep 2024; latest on Jun 18, 2026. Located in CAMBRIDGE, MA.
Companies Foster-Cheek Kaye I has filed insider reports for
- AGIOS PHARMACEUTICALS, INC. (AGIO): Director
- Prime Medicine, Inc. (PRME): Director
Foster-Cheek Kaye I
CIK: 0001312622
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
ExerciseDirect2.8K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
AwardDirectStock options (right to buy)
15K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
AwardDirectRestricted stock units
2.9K shares- - Jun 5, 2026PRME
Prime Medicine, Inc.
AwardDirectStock Option (right to buy)
75K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
AwardDirectStock Option (right to buy)
9K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
DispositionDirectStock Option (right to buy)
39.1K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
AwardDirectStock Option (right to buy)
39.1K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
AwardDirectStock Option (right to buy)
45K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
DispositionDirectStock Option (right to buy)
45K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
DispositionDirectStock Option (right to buy)
13.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 18, 2026 |  AGIO AGIOS PHARMACEUTICALS, INC. | Exercise | 2,816 | - | $0 | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award Stock options (right to buy) | 14,950 | - | - | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award Restricted stock units | 2,927 | - | - | Direct |
| Jun 5, 2026 |  PRME Prime Medicine, Inc. | Award Stock Option (right to buy) | 75,000 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award Stock Option (right to buy) | 9,006 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition Stock Option (right to buy) | 39,062 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award Stock Option (right to buy) | 39,062 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award Stock Option (right to buy) | 45,000 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition Stock Option (right to buy) | 45,000 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition Stock Option (right to buy) | 13,510 | - | - | Direct |
1-10 of 16 transactions